<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Announces Upcoming Phase 1/2 Clinical Trial for Innovative Diabetic Foot Ulcer Therapy at Advanced Wound Care <a href="https://laohu8.com/S/SMMT">Summit</a>
FibroBiologics Inc. has announced the upcoming presentation of their recent research advances at the Advanced Wound Care Summit USA in Boston, Massachusetts. The company's Founder and CEO, Pete O'Heeron, is set to present on July 15, 2025, focusing on fibroblast-based technology for wound healing and psoriasis. The presentation will highlight FibroBiologics' CYWC628 therapy, which represents a novel approach to treating diabetic foot ulcers by leveraging the body's natural regenerative processes. This therapy is part of their Phase 1/2 clinical trial, which is scheduled to begin later this year. The summit will feature various industry leaders discussing innovations in wound care and is an opportunity for FibroBiologics to showcase their potential contributions to the field. Results of the clinical trial have not yet been presented as the trial is still in preparation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492657-en) on July 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。